We modeled the lifetime outcomes after tri-modality therapy versus radical cystectomy in patients with muscle-invasive bladder cancer and compared the 2 strategies' effectiveness using the endpoint of qualityadjusted life years. We found that the use of tri-modality therapy resulted in greater quality of life than radical cystectomy. Introduction: There are limited randomized data comparing radical cystectomy (RC) with bladder-sparing tri-modality therapy (TMT) in the treatment of muscle-invasive bladder cancer (MIBC). Both strategies are thought to have similar survival outcomes with different morbidity profiles. We compare the effectiveness of TMT and RC using decisionanalytic modeling and the endpoint of quality-adjusted life years (QALYs). Patients and Methods: Using a Markov model, we simulated the lifetime outcomes after TMT versus RC AE neoadjuvant chemotherapy for 67-year-old patients with clinical stage T2-T4aN0M0 MIBC. Model probabilities and utilities were extracted from the literature. The incremental effectiveness was reported in QALYs and sensitivity analyses were performed. Results: For all patients with MIBC, although the model showed identical survival, TMT was the most effective strategy with an incremental gain of 0.59 QALYs over RC (7.83 vs. 7.24 QALYs, respectively). When limiting the model to favorable, contemporary cohorts in both the TMT and RC strategies, TMT remained more effective with an incremental gain of 1.61 QALYs (9.37 vs. 7.76 QALYs, respectively). One-way sensitivity analyses demonstrated the model was sensitive to the quality of life parameters (ie, the utilities) for RC and TMT. When testing the 95% confidence interval of the RC utility parameter the model demonstrated an incremental gain with TMT from À0.54 to 4.23 QALYs. Probabilistic sensitivity analysis demonstrated that TMT was more effective than RC for 63% of model iterations. Conclusions: This modeling study found that treatment of MIBC with organ-sparing TMT in appropriately-selected patients may result in a gain of QALYs relative to RC.
Introduction
Bladder cancer (BC) is the seventh most common cancer in the United States and accounts for nearly 80,000 new cases and 17,000 deaths per year. 1 Nearly 25% of new cases are muscle-invasive BC (MIBC) (T2-T4 disease), which has a 5-year survival of < 15% without treatment. 2 Organ-removing radical cystectomy (RC) with pelvic lymph node dissection has historically been considered the standard of care. RC is a complex urologic procedure most effectively delivered by experienced surgeons when considering the risk for prolonged hospitalizations and substantial morbidity and mortality.
An increasing trend in organ-preserving approaches across multiple cancer types (eg, breast, kidney, prostate, anal, and laryngeal cancers) includes the development of tri-modality therapy (TMT) for MIBC, a multidisciplinary bladder-sparing approach involving transurethral resection of the bladder tumor, chemotherapy, and radiation therapy that achieves preservation of the native bladder in over 70% of patients. 4 ,5 RC and TMT are both definitive treatment options for MIBC recommended by professional society guidelines, [6] [7] [8] [9] and data has suggested similar survival but different morbidity profiles. 4, 5, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] There are limited high-level data directly comparing RC with TMT e this is illustrated in part by the randomized trial SPARE (Selective bladder Preservation Against Radical Excision) closing early owing to low accrual. 20, 21 Therefore, the purpose of this study is to directly compare the effectiveness of TMT with RC using the primary endpoint of quality-adjusted life years (QALYs) with decision-analytic modeling.
Patients and Methods

Model Overview
We developed a Markov model to compare the effectiveness of definitive treatment with TMT versus RC, in patients with localized urothelial cell MIBC, American Joint Committee on Cancer clinical stage T2-T4aN0M0. 6 The model was run for (1) all patients with MIBC, 4, 22 (2) limiting the RC strategy to those with more contemporary, favorable low-risk disease, defined as having clinical T2 disease without hydroreteronephrosis, lymphovascular invasion, or micropapillary disease (treated from 2000-2010), 23 and (3) limiting the TMT strategy to those from a more contemporary cohort (treated from 2005-2013) who had more favorable outcomes. 4 A Markov model simulates patients over time and allows transitions between different health states based on probabilities (simplified model shown in Figure 1 ; more detailed model shown in the Supplemental Figure 1 in the online version). Transitions occur at fixed-time increments (cycles). As the duration of a TMT treatment protocol approaches nearly 1 year, 24 this discrete-time model uses a 12-month cycle length with patients entering at age 67, the median age of this population, 4, 25 and terminating at death or age 100 (33 cycles).
Model Parameters
The probabilities and utilities for the model are shown in Table 1 . Hypothetical patients start in the disease health state and enter 1 of 2 strategies: TMT or RC AE neoadjuvant chemotherapy (NAC). Patients in the TMT strategy may have a complete response (CR) and be rendered without disease (no evidence of disease [NED]) or may have an incomplete response to TMT and have a chance at immediate salvage RC. TMT CR NED patients may recur at a later cycle and have a chance at a delayed salvage RC. TMT probabilities are based primarily on the experience of TMT for MIBC at Massachusetts General Hospital (MGH). 4 This prospective cohort was chosen because of the large number of patients, 
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Effectiveness of Tri-modality Therapy recently updated outcomes with long follow-up, and the detailed cancer control statistics reported (ie, disease-free survival, clinical response, and salvage RC rates). Patients with MIBC in the RC strategy may be candidates for NAC, the probability of which is based on national practice patterns. 26 Irrespective of NAC, all RC strategy patients have a probability of successfully undergoing RC. RC probabilities for all patients with MIBC are derived from BA06 30894, a large international multicenter randomized trial of nearly 1000 patients. 22 This cohort was chosen because of the large number of patients, long follow-up, the detailed cancer control statistics for RC patients with or without NAC, and the use of a standard National Comprehensive Cancer Network-recommended NAC regimen. 6 To account for heterogeneity between parameterderived populations, we also ran the model using RC strategy parameters derived from the MD Anderson Cancer Center (MDACC, Houston, TX) more contemporary, favorable, low-risk MIBC cohort published as a retrospective experience of 199 low-risk patients (clinical T2) that did not use NAC, had shorter follow-up, and reported less granular cancer control statistics. 23 Finally, because the MDACC favorable, low-risk patients were treated in a more modern era (2000-2010), we also ran the model using TMT strategy parameters derived from a modern cohort (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) , who have also demonstrated more favorable outcomes. 4 Patients in either strategy are at risk of death or progression to advanced, nonsalvageable BC from any health state and during any cycle. The non-salvageable health state includes those patients who develop metastatic disease. 30 The probability of death is based on Social Security actuarial life tables and published survival curves. Some probabilities, such as the risk of death after RC or TMT, which incorporates operative/postoperative RC deaths or deaths during TMT, were modeled as piece-wise time-varying parameters ( Table 1) . We assumed that patients alive 7 years after their diagnosis have been cured of their BC, which is consistent with MIBC disease-specific survival curves. 4 Health state utilities were largely derived from literature explicitly evaluating patient utility values in patients with BC 30 directly comparing TMT and RC. 15 The reported EuroQOL EQ-5D 3L 31 Sensitivity Analyses. For the sensitivity analyses, we varied parameters for all patients with MIBC over their 95% confidence interval (CI) thereby revealing the effect of plausible parameter values on the endpoint of QALYs. A 1-way or 2-way deterministic sensitivity analysis varies a single or 2 parameters at a time, respectively; a 1-way sensitivity analysis was performed on all possible model parameters.
Probabilistic sensitivity analysis addresses all parameter uncertainties simultaneously by randomly choosing values for each parameter based on probabilistic distributions; beta distributions were used. 32 Ten thousand different randomly chosen sets of parameter values were selected, and each set had 10,000 simulated patients run through the model via Monte Carlo simulation for a total of 100,000,000 model iterations. The Monte Carlo microsimulation simulates individual patients traveling the model and aggregates the results to demonstrate the percent of iterations in which a given strategy produced the greatest QALYs.
Results
Base Case Analysis
The base case analysis for all patients with MIBC produced an unadjusted expected value of 8.89 and 8.89 life years (LYs) and an adjusted expected value of 7.83 and 7.24 QALYs for TMT versus RC, respectively, demonstrating an incremental gain of 0.59 QALYs in favor of TMT ( Table 2) . The model's 5-, 10-, and 15-year survival rates for the TMT and RC strategies were 51%, 31%, and 24% versus 50%, 34%, and 26%, respectively (Tables 3 and 4) .
Using parameters derived from a low-risk MIBC population for the RC strategy, the base case analysis produced an unadjusted expected value of 8.89 and 9.34 LYs and an adjusted expected value of 7.83 and 7.76 QALYs for TMT versus RC, respectively, demonstrating an incremental gain of 0.07 QALYs in favor of TMT (Table 2) .
When parameters were derived from a more contemporary cohort of TMT patients, who have demonstrated more favorable Effectiveness of Tri-modality Therapy outcomes, the base case analysis produced an unadjusted expected value of 10.52 LYs and an adjusted expected value of 9.37 QALYs for TMT, demonstrating an incremental gain of 1.61 QALYs in favor of TMT over the RC strategy in the low-risk cohort (Table 2 ).
Sensitivity Analysis
The 1-way sensitivity analyses performed on all patients with MIBC are summarized in Figure 2 . The incremental effectiveness (QALYs) of TMT versus RC was sensitive to the QoL parameters (the utilities) for RC and TMT. TMT was more effective than RC when (1) the RC utility was < 0.92 (when testing the 95% CI for the RC utility of 0.32 to 1.0, the incremental effectiveness of TMT versus RC ranged from 4.23 to À0.54 QALYs) or (2) when the TMT utility was > 0.82 (when testing the 95% CI for the TMT utility of 0.60 to 1.0, the incremental effectiveness of TMT versus RC ranged from À1.68 to 1.26). To further illustrate the relationship between 2 of the model's sensitive parameters, the utilities of RC and TMT, a 2-way sensitivity analysis was done varying these parameters over their 95% CIs as shown in Figure 3 , which demonstrates for which utility values one strategy is superior (by QALYs) to the other. Additionally, we ran a Monte Carlo microsimulation by randomly sampling from only the distributions of the TMT and RC utilities (10,000 samples) and running the model 10,000 times for each sample (100,000,000 model iterations) and found the TMT strategy was superior to RC by QALYs for 66% of all model iterations.
The only parameters, other than the utilities of TMT and RC, where the effectiveness of TMT was not uniformly greater than RC on 1-way sensitivity analysis were from the TMT strategy and included when the 7-year probability of death after a CR was 8% greater than the mean value (when testing the 95% CI for this parameter of À33% to þ38%, the incremental effectiveness of TMT ranged from À0.97 to 2.07 QALYs), and also the 7-year probability of death in those who underwent an immediate salvage cystectomy owing to an incomplete response to TMT, and also the probability of relapse after a complete response. The model was not highly sensitive to the probability of death in the RC strategy or to the probability of a CR in the TMT strategy when these parameters were varied over their 95% CIs. Probabilistic sensitivity analysis demonstrated that TMT was more effective than RC for 63% of model iterations (see Supplemental Figure 2 in the online version).
Because a national underutilization of NAC for MIBC persists despite level 1 evidence demonstrating improved survival, 26, 27 we also ran a 1-way sensitivity analysis on the probability of receiving NAC (from 0% to 100%) to probe the impact on our model's outcome of uniform NAC adoption. TMT was more effective than RC AE NAC by 0.66 QALYs (0% receiving NAC) to 0.29 QALYs (100% receiving NAC).
Discussion
This comparative effectiveness analysis found that TMT for MIBC resulted in an incremental gain in effectiveness of 0.59 more QALYs compared with RC (7.83 versus 7.24 QALYs, respectively). Sensitivity analyses demonstrated that the gain in QALYs with TMT is driven largely by the QoL differences (the utilities) between TMT and RC. This is further illustrated by our model's identical expected life years (8.89 ) and similar survival rates for the TMT and RC strategies. It is interesting that the 2 independently modeled strategies using parameters derived from different data sets had nearly identical survival outcomes and supports recently published data suggesting similar survival outcomes for TMT and RC. 5, 14 Furthermore, probabilistic sensitivity analysis via Monte Carlo simulation demonstrated that TMT was more effective by the QALY metric for nearly two-thirds of all model iterations. Additionally, when having RC-strategy parameters derived from a more favorable, low-risk MIBC cohort with better survival outcomes, the model demonstrated a small but persistent incremental gain with TMT (0.07 QALYs).
The clinical implications of these findings are that, although the 2 strategies appear to have similar survival outcomes, TMT may be superior to RC with respect to QALYs and therefore be a preferred approach to the definitive management of MIBC in patients who are appropriate candidates for this treatment approach. These findings demonstrate for the first time the magnitude of QALY benefit patients may stand to gain with TMT and preservation of the native bladder (0.59 QALYs). Selection criteria for appropriate TMT candidates may be those with (1) tumors < 5 cm, (2) solitary tumors, (3) minimal to no hydronephrosis, (4) good bladder function, and (5) no multifocal carcinoma in situ.
14 It is plausible that this treatment strategy is particularly appealing for those patients with comorbidities that make them less preferable surgical candidates; however, these decisions are likely best made in the multidisciplinary setting. 14 Additionally, it is plausible that the QALY benefit with TMT may be more apparent in patients treated with modern radiation (and TMT) as this cohort has been shown to have more favorable outcomes and thus stands to have the most QALY gain; we found a 1.61 incremental QALY gain with TMT versus RC when comparing favorable contemporary cohorts. Of note, surgical techniques have also improved in the modern era, and RC complications have likely decreased with enhanced recovery after surgery programs and robot-assisted surgery, techniques which may temper these findings.
35,36
Our study has several limitations that require further discussion. First, our study did not look at the incremental increase in cost of definitive treatment for MIBC with TMT versus RC. Considering the multimodality nature of TMT, using transurethral resection of the bladder tumor, radiation therapy, chemotherapy, surveillance cystoscopies, and managing any tumor recurrences identified in the native bladder, it may be that TMT is more costly than RC AE NAC. Additionally, long-term radiation-related complications (eg, readmissions, secondary procedures, second malignancies) could further increase the cost of TMT. However, given the incremental gain in effectiveness in QALYs with TMT, for which society would be willing to pay $100,000/QALY (assuming a willingness to pay threshold of $100,000 per QALY 37 ), TMT may remain more costeffective; RC can come with costly surgical morbidity and hospital re-admissions, and data exists informing the mean cost of RC to be over $50,000. 30, 38 Regardless, further cost analyses addressing this question are warranted. Second, these findings rely on the validity of parameters used by the model, which are derived from the best literature available. We used national practice patterns to define NAC utilization, a rate that may be lower than tertiary care centers, and therefore may lead to an overestimate of QALYs gained with TMT. This is reflected in our sensitivity analysis showing a smaller gain of 0.29 QALYs with TMT when there is 100% NAC utilization. Additionally, the utilities were derived from a recent study that collected and directly compared the QoL of TMT and RC using well-validated instruments. 15, 31 Their findings, which are consistent with the existing literature, 10 used data obtained via survey with a response rate of nearly 80% and, with a long median follow-up period of over 5 years, should account for longitudinal events such as non-MIBC recurrences, surveillance cystoscopies, and follow-up visits. However, such a follow-up period may also introduce recall and selection bias 15 ; therefore, our study is hypothesis-generating and requires further prospective validation. These utilities were defined in patients treated at large, academic, tertiary referral centers, which limits generalizability, and one should be cautious extrapolating these findings to the community setting. They were also defined in a population in whom the majority of cystectomies were open (71% open vs. 28% robotic-assisted) and followed by ileal conduit diversion (82% with ileal conduit vs. 17% with orthotopic neobladders), which may have QoL implications. Fortunately, head-tohead prospective QoL and outcome data on RC and TMT may be forthcoming. 5, 14 The recent development of reliable and valid BC-specific patient-reported QoL instruments (eg, the Bladder Utility Symptom Scale) will help establish BC-specific utilities and facilitate such investigations. 39 Finally, as in all models, practical simplifying assumptions must be made. For example, we terminated the model at age 100, likely a safe assumption, as the probability of living to age 100 in our model was < 0.5%. In order to limit the number of assumptions and maintain the robustness and fidelity of the model, we looked at all patients with MIBC, for which the best outcome data are available, and we were unable to stratify by important disease characteristics, which may play a critical role in the decision of a multidisciplinary team recommending one definitive treatment modality over the other (ie, age, T stage, presence of hydronephrosis, volume of disease, multifocal disease, performance status, or comorbidity). For example, the non-utility model parameters for the TMT strategy were derived from an older population with likely more comorbidities but less advanced clinically staged tumors. 4, 22 The RC strategy non-utility parameters were derived from populations that likely included patients who may not have been candidates for TMT because of adverse disease characteristics. Nevertheless, when the RC strategy was limited to patients with more favorable low-risk disease, a small incremental gain in QALYs with TMT persisted. Still, there are patients who, based on their tumor burden, will not be good candidates for TMT, and this must be taken into account when selecting patients for this treatment strategy.
Conclusions
We demonstrated a gain of 0.59 QALYs with TMT relative to RC. A gain with TMT persisted when limiting the model to more favorable, contemporary cohorts. These findings are supported by 1-way and higher-order sensitivity analyses and suggest an effectiveness in favor of TMT. This supports consideration of this modality for appropriately selected patients with MIBC in the multidisciplinary setting, and motivates further investigation into the QoL consequences of these treatment modalities.
Clinical Practice Points
How RC compares with bladder-sparing TMT in the treatment of MIBC is unknown. We modeled the lifetime outcomes after TMT versus RC in patients with MIBC and compared the 2 strategies' effectiveness using the endpoint of quality-adjusted life years. We found that the use of TMT resulted in greater QoL than RC. This supports consideration of this modality for appropriatelyselected patients with MIBC in the multidisciplinary setting, and motivates further investigation into the QoL consequences of these treatment modalities.
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